Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innate Pharma SA ( (FR:IPH) ) just unveiled an announcement.
On July 4, 2025, Innate Pharma S.A. announced its total number of shares outstanding and voting rights as of July 3, 2025. The company reported 92,183,523 ordinary shares and a total of 92,962,943 theoretical voting rights. This disclosure ensures market transparency and informs stakeholders about the company’s shareholding structure, which is crucial for regulatory compliance and investor relations.
The most recent analyst rating on (FR:IPH) stock is a Buy with a EUR5.70 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes innovative approaches to harness the innate immune system through three therapeutic strategies: multi-specific NK Cell Engagers via its ANKET® platform, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs). Innate Pharma collaborates with biopharmaceutical companies like Sanofi and AstraZeneca and is listed on Euronext Paris and Nasdaq.
YTD Price Performance: -20.97%
Average Trading Volume: 110,303
Technical Sentiment Signal: Strong Sell
Current Market Cap: €140.6M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.